DexCom, Inc. DXCM
Regular-session close
After hours · Nov 20, 7:54 PM ET
- YTD
- +19.51%
- 1 year
- +35.78%
5D -4.35 (-5.20%)
- Market cap
- 29.58B
- Revenue (ttm)
- 5.10B
- Profit margin
- 19.42%
- EPS (ttm)
- 2.54
- Shares out
- 372.95M
- P/E ratio
- 31.23
- Forward P/E
- 25.30
- YTD return
- +19.51%
- 1-year return
- +35.78%
- 50-day average
- 84.01
- Volume
- 4.61M
- Avg volume
- 4.17M
- Open
- 80.48
- Previous close
- 80.19
- Day's range
- 78.75 – 81.58
- 52-week range
- 57.56 – 92.34
- Beta
- 1.44
- Analysts
- Strong Buy
- Price target
- 98.58 (+24.3%)
- Earnings date
- Feb 11, 2027
Key statistics
- 200-day average
- 75.27
- Enterprise value
- 29.48B
- PEG ratio
- 1.30
- Price / sales
- 5.80
- Price / book
- 11.67
- Revenue growth
- 11.20%
- Free cash flow
- 811.90M
- Total cash
- 1.82B
- Total debt
- 1.39B
- Return on equity
- 37.67%
- Short % of float
- 4.94%
Fundamental scorecard
18 of 25 checks passed on DXCM’s reported financials
18of 25 checks passed
- Value 3 of 5
- Growth 5 of 5
- Profitability 5 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 79.00
- Target (mean)
- 98.58
- Target (high)
- 120.00
- Strong buy4
- Buy22
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 0.717.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 0.71 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 0.675 | 0.73 | +0.05 | +8.15% |
| Jul 30, 2026 | Jun 30, 2026 | 0.611 | 0.70 | +0.09 | +14.57% |
| Apr 30, 2026 | Mar 31, 2026 | 0.4656 | 0.56 | +0.09 | +20.27% |
| Feb 12, 2026 | Dec 31, 2025 | 0.65 | 0.68 | +0.03 | +4.62% |
| Oct 30, 2025 | Sep 30, 2025 | 0.576 | 0.61 | +0.03 | +5.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | UBS | main | Buy | Buy |
| Oct 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 30, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | StoneX | main | Buy | Buy |
| Oct 12, 2026 | BTIG | main | Buy | Buy |
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- dexcom.com
News
Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms
Here's How Much $1000 Invested In DexCom 10 Years Ago Would Be Worth Today
DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
DexCom, Inc. $DXCM Shares Sold by Aberdeen Group plc
Commonwealth Equity Services LLC Purchases 10,738 Shares of DexCom, Inc. $DXCM Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97
JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85
Barclays Maintains Overweight on DexCom, Raises Price Target to $120
StoneX Maintains Buy on DexCom, Raises Price Target to $93
Your note
Sign in to keep a note on DXCM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMAN STEVEN R | Director | Stock Award(Grant) | May 27, 2026 | 69,232 |
| BROWN MICHAEL JON | Officer | Sale | Nov 15, 2026 | 95,034 |
| COLEMAN JON | Officer | Sale | Jun 3, 2026 | 95,450 |
| COLLINS RICHARD ALEXANDER | Director | Stock Award(Grant) | May 27, 2026 | 45,767 |
| FOLETTA MARK G | Director | Sale | Aug 2, 2026 | 0 |
| LEACH JACOB STEVEN | Chief Executive Officer | Stock Award(Grant) | Mar 5, 2026 | 469,106 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.32% | 38,498,188 | 3.05B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.62% | 24,704,482 | 1.96B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.31% | 19,791,156 | 1.57B | Sep 29, 2026 |
| State Street Corporation | 5.07% | 18,896,988 | 1.50B | Sep 29, 2026 |
| Invesco Ltd. | 4.28% | 15,968,909 | 1.27B | Sep 29, 2026 |
| BAILLIE GIFFORD & CO | 3.89% | 14,521,620 | 1.15B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.28% | 12,250,468 | 971.71M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.68% | 10,000,154 | 793.21M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.24% | 8,360,947 | 663.19M | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.11% | 7,879,739 | 625.02M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.44% | 5,384,037 | 427.06M | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.35% | 5,028,467 | 398.86M | Sep 29, 2026 |
